Terms: = Skin cancer AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Staging
5 results:
1. Efficacy and safety of HpD-PDT for Extramammary Paget's Disease refractory to conventional therapy: A prospective, open-label and single arm pilot study.
Wang D; Wang P; Li C; Zhou Z; Zhang L; Zhang G; Wang X
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102670. PubMed ID: 34883272
[TBL] [Abstract] [Full Text] [Related]
2. Novel Prognostic Models Predicting the cancer-Specific Survival in Patients with Cutaneous Melanoma Based on Metastatic Lymph Node Status.
Li W; Xu X; Zhang Y
Ann Surg Oncol; 2021 Aug; 28(8):4572-4581. PubMed ID: 33432490
[TBL] [Abstract] [Full Text] [Related]
3. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG; Marshall A; Dunn JA; Middleton MR; Nathan PD; Gore M; Davidson N; Nicholson S; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Young G; Lorigan P
Lancet Oncol; 2014 May; 15(6):620-30. PubMed ID: 24745696
[TBL] [Abstract] [Full Text] [Related]
4. A critical review of melanoma pathology reports for patients referred to the Western Australian Melanoma Advisory Service.
Monshizadeh L; Hanikeri M; Beer TW; Heenan PJ
Pathology; 2012 Aug; 44(5):441-7. PubMed ID: 22772338
[TBL] [Abstract] [Full Text] [Related]
5. CD30 (Ki-1)-positive malignant lymphomas: clinical, immunophenotypic, histologic, and genetic characteristics and differences with Hodgkin's disease.
Filippa DA; Ladanyi M; Wollner N; Straus DJ; O'Brien JP; Portlock C; Gangi M; Sun M
Blood; 1996 Apr; 87(7):2905-17. PubMed ID: 8639911
[TBL] [Abstract] [Full Text] [Related]
